Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Widely Used in Asia, Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention
    STROKE ALERT

    Widely Used in Asia, Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention

    August 1, 2020
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention

    Dual Antiplatelet Therapy With Cilostazol for Secondary Stroke Prevention (LB3)

    Long-Term Results of Dabigatran vs Warfarin for Stroke Prevention in AF Patients

    Related Products

    Alzheimer’s Disease: What the Primary Care Physician Needs to Know

    All Access Subscription: Online

    Keywords

    stroke

    vessel

    brain

    cognitive

    ischemic

    cilostazol

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, New York Presbyterian/Weill Cornell Medical College

    Dr. Fink reports no financial relationships relevant to this field of study.

    SOURCE: McHutchison C, Blair GW, Appleton JP, et al. Cilostazol for secondary prevention of stroke and cognitive decline: Systematic review and meta-analysis. Stroke 2020; July 10. doi: 10.1161/STROKEAHA.120.029454. [Online ahead of print].

    Cilostazol is a phosphodiesterase 3 inhibitor widely used in Asia for secondary stroke prevention but approved for use in North America only for symptomatic peripheral vascular disease. In animal studies, it has been demonstrated to have weak antiplatelet effects, but it stabilizes the endothelium and appears to aid myelin repair. It has been theorized that cilostazol might be beneficial in preventing the progression of small vessel disease in the brain and, therefore, may have a secondary effect in preventing vascular dementia.

    The investigators undertook a systematic review and meta-analysis of randomized controlled trials of cilostazol to prevent stroke, cognitive decline, or small vessel disease progression in studies published from Jan. 1, 2019, until July 16, 2019, and they pooled the data for analysis. They calculated odds ratios (ORs) and 95% confidence intervals (CIs) for recurrent ischemic stroke, hemorrhagic stroke, death, and adverse symptoms.

    They identified 20 randomized controlled trials, which included 10,505 patients, 18 studies in ischemic stroke and two in cognitive impairment. In a pooled analysis, researchers found that cilostazol decreased recurrent ischemic stroke (OR, 0.68; P < 0.0001), hemorrhagic stroke (OR, 0.43; P = 0.0001), deaths (OR, 0.64; P < 0.0009), and systemic bleeding (OR, 0.73; P = 0.04), but they noted an increased incidence of headache and palpitations when compared to placebo, aspirin, or clopidogrel. Cilostazol appeared to have greater benefit when given long term vs. short term (greater than six months) and did not increase hemorrhages. The data were insufficient to assess its effects on cognition, imaging, or functional outcomes.

    The majority of these studies were performed in Asia-Pacific countries, and more trials in Western countries should be initiated to assess the effects of cilostazol treatment on cognitive decline and functional outcomes, as well as on the progression of small vessel disease in the brain. The studies from Asia suggest that it is a promising treatment, but it has not been studied sufficiently in clinical trials.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 39, No. 12) - August 2020
    August 1, 2020

    Table Of Contents

    Clinical Trials of IL-6 Inhibitors for the Treatment of Neuromyelitis Optica Spectrum Disorders

    Brachial Plexopathy Localization in Patients with Cancer

    Anticoagulation in Patients with Ischemic Stroke Related to Atrial Fibrillation, Following Reperfusion Therapy

    Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis

    Widely Used in Asia, Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention

    Should Patients with Ischemic Stroke and Large Vessel Occlusions Go Directly to Endovascular Thrombectomy?

    Mobile Stroke Units: What Is the Best Way to Use Them?

    COVID-19 Infection Increases Stroke Risk by Almost Eight Times the Stroke Risk with Influenza

    Ticagrelor Added to Aspirin Reduces Long-Term Risk of Recurrent Stroke or Death After Ischemic Stroke or TIAs

    We’d Love to Hear from You!

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing